Coronary artery disease: Complex coronary disease in the post-SYNTAX era.
Should patients with high-risk coronary artery disease be treated with CABG or receive drug-eluting stents? The SYNTAX trial aimed to define the optimal revascularization strategy for patients with previously untreated three-vessel and/or left main coronary artery disease.
Tarantini
Giuseppe
G
D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000209:etiology; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D015337:Multicenter Studies as Topic; D017239:Paclitaxel / Q000008:administration & dosage*; D018579:Patient Selection; D011446:Prospective Studies; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D017239:Paclitaxel